Abstract
A patient with ataxia telangiectasia was treated with recombinant interleukin-2 (rIL-2) and the resulting immunological effects evaluated. The patient lacked IL-2 production, and immunoglobulin synthesis was also impaired. Treatment with IL-2 selectively increased serum IgM without any significant side effects. Therapy also restored B-cell function in vitro, IgM production as well as the proliferative response to Staphylococcus aureus strain Cowan I. These results suggest that IL-2 treatment may correct both T-cell and B-cell defects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AT:
-
ataxia telangiectasia
- ELISA:
-
enzymelinked immunosorbent assay
- 3H-TdR:
-
tritiated thymidine
- MNC:
-
mononuclear cells
- PHA:
-
phytohaemagglutinin
- PMA:
-
phorbol myristate acetate
- PWM:
-
pokeweed mitogen
- rIL-2:
-
recombinant interleukin 2
- SAC:
-
Staphylococcus areus strain Cowan I
References
Diamanstein T, Osawa H (1986) The interleukin-2 receptor, its physiology and a new approach to a selective immunosuppressive therapy by anti-interleukin-2 receptor monoclonal antibodies. Immunol Rev 92:5–27
Dopfer R, Niethammer D, Peter HH, Kniep EM, Monner DA, Mühlradt PF (1984) In vivo effects of interleukin 2 on lymphocyte subpopulations in a patient with a combined immunodeficiency. Immunobiology 167:452–461
Flomenberg N, Welte K, Mertelsmann R, Kernan N, Clobanu N, Venuta S, Feldman S, Kruger G, Kirkpatrick D, Dupont B, O'Reilly R (1983) Immunologic effects of interleukin 2 in primary immunodeficiency diseases. J Immunol 130:2644–2650
Ford R, Mehta S, Franzini D, Montagna R, Lachman L, Maizel A (1981) Soluble factor activation of human B lymphocytes. Nature 294:261–263
Gillis S, Smith KA (1977) Long term culture of tumor-specific cytotoxic T-cells. Nature 268:154–156
Gramatzti M, Nüsslein H, Burmester GR, Rödl W, Heyder N, Grote W, Monner DA, Mühlradt PF, Kalden JR (1986) Intralymphatic interleukin 2 treatment in patients with acquired immunodeficiency syndrome: preliminary experience in three cases. Immunobiology 172:438–447
Henny CS, Kuribayashi K, Kern DE, Gillis S (1981) Interleukin 2 augments natural killer cell activity. Nature 291:335–338
Le thi Bich-Thuy, Fauci AS (1985) Direct effect of interleukin 2 on the differentiation of human B cells which have not been pre-activated in vitro. Eur J Immunol 15:1075–1079
Leonard WJ, Depper JM, Uchiyama T, Smith KA, Waldmann TA, Green WC (1982) A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature 300:267–269
Lotze MT, Frana LW, Sharrow SO, Robb RJ, Rosenberg SA (1985) In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin-2. J Immunol 134:157–166
Mingari MC, Gerrosa F, Carra G, Accola RS, Moretta A, Zubler RH, Waldmann TA, Moretta L (1984) Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 312:641–643
Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007–1008
Nakagawa T, Hirano T, Nakagawa N, Yoshizaki K, Kishimoto T (1985) Effect of recombinant IL 2 and γ-IFN on proliferation and differentiation of human B cells. J Immunol 134:959–966
Ralph P, Jeong G, Welte K, Mertelsmann R, Rabin H, Henderson LE, Souza LM, Boone TC, Robb RJ (1984) Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL-2. J Immunol 133:2442–2445
Saiki O, Ralph P (1981) Induction of human immunoglobulin secretion. I. Synergic effect of B cell mitogen Cowan I plus T cell mitogen or factor. J Immunol 127:1044–1047
Saiki O, Ralph P, Cunningham-Rundles C, Good RA (1982) Three distinct stage of B-cell defects in common varied immuno-deficiency. Proc Natl Acad Sci USA 79:6008–6012
Saiki O, Shimizu M, Saeki Y, Kishimoto S, Kishimoto T (1984) Dissociation in the production of B cell-stimulation factors (BCGF and BCDF) and interleukin 2 by T cells from a common variable immunodeficient patient. J Immunol 133:1920–1924
Tanaka T, Saiki O, Doi S, Hatakeyama M, Doi T, Kohno T, Mori H Fujii M, Sugamura K, Negoro S, Taniguchi T, Kishimoto S (1987) Functional interleukin 2 receptors on B cells lacking Tac antigens. Eur J Immunol 17:1379–1381
Taniguchi T, Matsui H, Fujita T, Takaoka C, Kashima N, Yoshimoto R, Hamuro J (1983) Structure and expression of a cloned cDNA for human interleukin-2. Nature 302:305–310
Volkman DJ, Lane HC, Fauci AS (1982) Antigen-induced in vitro antibody production by humans: a model for B cell activation and immunoregulation. Proc Natl Acad Sci USA 78:2528–2531
Waldmann TA, Goldman CK, Robb RJ, Depper JM, Leonard WJ, Sharrow SO, Bongiovanni KF, Korsmeyer SJ, Green WC (1984) Expression of interleukin 2 receptors on activated human B cells. J Exp Med 160:1450–1466
Weyard CM, Goronzy J, Dallman MJ, Fathman CG (1986) Administration of recombinant interleukin 2 in vivo induces a polyclonal IgM response. J Exp Med 163:1607–1612
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Doi, S., Saiki, O., Hara, T. et al. Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient. Eur J Pediatr 148, 630–633 (1989). https://doi.org/10.1007/BF00441517
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00441517